Corrigendum to "Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer" [Eur J Cancer 180 (2023) 184-185]
- PMID: 38310078
- DOI: 10.1016/j.ejca.2024.113559
Corrigendum to "Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer" [Eur J Cancer 180 (2023) 184-185]
Erratum for
-
Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer.Eur J Cancer. 2023 Feb;180:184-185. doi: 10.1016/j.ejca.2022.11.018. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36581473 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
